Potent Bcrp Inducers
Severe
Textbook
Reduced efficacy of tenofovir alafenamide fumarate.
Avoid drugs that strongly affect BCRP.
Source: G&G 14e · p1241
Drug reference
tenofovir alafenamide fumarate
Nucleotide analogue · Antiviral, Hepatitis B agent
Nucleotide analogueAntiviral, Hepatitis B agent
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
2 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactions
- Potent Bcrp InducersSevereTextbookG&G 14e · p1241
- Potent P Gp InducersSevereTextbookG&G 14e · p1241
Mechanism
Tenofovir alafenamide fumarate is a prodrug that is taken up into cells, deesterified, concentrated, and phosphorylated to tenofovir diphosphate. Tenofovir diphosphate is a competitive inhibitor of reverse transcriptase for both HBV and HIV-1, causing chain termination when incorporated into DNA.
Indications
HBV infection (preferred agent)Indefinite treatment for patients with cirrhosis
Dosing
- Adult
- 25 mg once daily
- Pediatric
- Adult dose for children weighing at least 45 kg
- Renal adjustment
- Not recommended for eGFR <15 mL/min/1.73 m2
Contraindications
- eGFR <15 mL/min/1.73 m2
Side effects
Common
NauseaRashDiarrheaDepressionWeaknessHeadache
Serious
- HBV flare-up upon sudden discontinuation
Drug interactions
Potent P Gp Inducers
Severe
Textbook
Reduced efficacy of tenofovir alafenamide fumarate.
Avoid drugs that strongly affect P-gp.
Source: G&G 14e · p1241
Related guidelines
Other Nucleotide analogue drugs
Ask House about tenofovir alafenamide fumarate
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team